🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. Sodium stibogluconate

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  2. Sonodynamic therapy(SDT)

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other terminated

    1 trial

  3. Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4

    Travere Therapeutics

    Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

    phase 2 small molecule active

    1 trial

  4. Stellate Ganglion Block injection with ropivicane

    United Therapeutics Europe Ltd

    Post Traumatic Stress Disorder (PTSD)

    phase 2 other completed

    1 trial

  5. Stem Cell Educator

    The First People's Hospital of Lianyungang

    Alopecia Areata

    phase 2 other active

    1 trial

  6. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  7. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  8. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  9. TACE with adebrelimab and bevacizumab

    The First People's Hospital of Lianyungang

    Adebrelimab

    phase 2 small molecule active

    1 trial

  10. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Telitacicept

    The First People's Hospital of Lianyungang

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  12. Temozolomide

    The First People's Hospital of Lianyungang

    Cytokine-Induced Killer Cells

    phase 2 small molecule active

    1 trial

  13. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  14. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial

  15. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  16. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  17. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  18. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  19. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

  20. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  21. TmBU conditioning Regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  22. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  23. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  24. Toripalimab

    The First People's Hospital of Lianyungang

    Adenocarcinoma of the Stomach

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources